Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Repligen: Very Strong Growth in Sales and Earnings Continues (RGEN, 29.37, Buy)

Investment Thesis

Repligenís operating business results continue to be very strong as second quarter bioprocessing sales increased 36%. For perspective, full…
Read more…

Repligen Makes An Excellent Acquisition (RGEN, Hold/ Buy, $19.04, free content)

The Bioprocessing Business of Refine Technology

Repligen (RGEN) has just announced the acquisition of Refine Technology. The primary reason for the…
Read more…

Repligen: Looking At 2014 and Beyond- Potential for EPS Growth (RGEN, $12.78) (Subscribers Only)

Investment Thesis

I think that Repligen's (RGEN) bioprocessing businesses is one of the best business models that I have seen in…
Read more…

Repligen: A Buy and Hold Stock: OPUS Promises to be a Dynamic New Product (RGEN; $9.87)

Report Summary
In this report, I go through a detailed sales, earnings and cash flow projections for the period 2013 through…
Read more…